SCHEMBL5216635

SCHEMBL5216635

FC(F)(F)c1ccccc1CNc1nc(Nc2ccc3[nH]cc(C4=CCNCC4)c3c2)ncc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 16/20 0.45
▸ PTK2B Q14289 12/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ NTRK3 Q16288 1/20 0.43
▸ NTRK2 Q16620 1/20 0.43
▸ STAT6 P42226 1/20 0.42
▸ AURKA O14965 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ CDC7 O00311 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ HIPK2 Q9H2X6 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213071 0.93 PTK2 (0.41) PTK2PTK2BJAK2STAT6AURKA
SCHEMBL5208214 0.89 PTK2 (0.61) PTK2PTK2BAURKABRD4
SCHEMBL5212938 0.88 PTK2 (0.61) PTK2PTK2BAURKABRD4
SCHEMBL5213023 0.85 PTK2 (0.63) PTK2PTK2BJAK2NTRK1TYK2
SCHEMBL5212767 0.85 ULK1 (0.47) PTK2PTK2BJAK2CDK2
SCHEMBL5213817 0.84 CDK1 (0.47) PTK2BJAK2AURKA
SCHEMBL5213474 0.84 PTK2 (0.61) PTK2PTK2B
SCHEMBL6211231 0.83 CDK1 (0.43) PTK2PTK2BJAK2NTRK1STAT6
SCHEMBL5212591 0.83 PTK2 (0.51) PTK2PTK2B
SCHEMBL6240449 0.82 CDK1 (0.43) PTK2PTK2BSTAT6CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 — — US claimed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 — — EP claimed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 — — WO claimed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 — — US claimed
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 — — US disclosed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 — — EP disclosed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 — — WO disclosed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth TYMS, TYMP, CCNA1 PTK2 3610/4885PTK2B 3168/4885JAK2 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback